12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ladostigil: Phase II started

Avraham began a 36-month, double-blind, placebo-controlled, international Phase II trial to evaluate 10 mg oral ladostigil daily in at least 200 patients. Avraham has an exclusive, worldwide license to develop and commercialize ladostigil...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >